RxSight Q3 2026 Results: Net Loss of $16.2M, Loss Widens
RxSight, Inc. reported 41,929,222 shares of common stock outstanding as of October 29, 2026. The company anticipates revenue growth through expanded sales territories and increased doctor adoption of its Light Adjustable Lens (LAL) system, while maintaining that current capital is sufficient to fund operations for at least 12 months.
- Key figure
- Net loss $16.2M